Skip to main content

Table 1 Current active trials in HNSCC with novel single agentsa

From: Genomically personalized therapy in head and neck cancer

Trial Number Trial phase Drug Pathway targeted Molecular selection Setting Status
NCT02429089 1 LEE011 Cell cycle No Recurrent, metastatic Recruiting
NCT02264678 1, 2 AZD6738 DNA repair No Recurrent, metastatic, in combination with chemotherapy or MEDI4736 or olaparib Recruiting
NCT02567396 1 Talazoparib DNA repair No Recurrent, metastatic Not yet recruiting
NCT01711541 1, 2 Veliparib DNA repair No Recurrent, metastatic, in combination with chemotherapy  
NCT02365662 1 ABBV-221 EGFR No Recurrent, metastatic Recruiting
NCT01345669 3 Afatinib ERBB No Placebo controlled post-chemoradiotherapy Recruiting
NCT01415674 2 Afatinib ERBB No Neoadjuvant Active, not recruiting
NCT01427478 3 Afatinib ERBB No Placebo controlled randomised phase 3, maintenance therapy after post-operative chemoradiotherapy Recruiting
NCT02131155 3 Afatinib ERBB No Placebo controlled adjuvant trial Recruiting
NCT02216916 2 HM781-36B ERBB No Recurrent, metastatic Recruiting
NCT02145312 2 BYL719 PI3K No Recurrent, metaststic Not yet recruiting
NCT02540928 2a AMG319 PI3K HPV-negative Placebo controlled neoadjuvant therapy Recruiting
  1. aClinical trials with immune checkpoint inhibitors are not included in this Table